文献速递病毒性肝炎细菌感染、耐药与抗菌药物

阿片类激动剂治疗项目中注射吸毒者丙型肝炎治疗模式的成本效果分析

Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究基于纽约布朗克斯随机试验数据,用决策分析模型比较四种HCV治疗模式对阿片类激动剂治疗患者的成本效果。结果显示所有治疗模式均较无干预大幅提高持续病毒学应答率,团体治疗和直接观察治疗在阈值下具有成本效果。

要点

  • 团体治疗与直接观察治疗在<10万美元/QALY阈值下91%模拟中被优选。
  • 直接观察治疗较团体治疗ICER>10万美元/QALY,效果略优但成本更高。

核心结论

  • 所有治疗模式均较无干预大幅提高持续病毒学应答率。
  • 团体治疗和直接观察治疗应被视为自服个体治疗的成本效果替代方案。

研究设计与样本

  • 基于纽约布朗克斯随机试验数据的决策分析模型。
  • 模拟队列具有与试验参与者相同的人口学特征。
  • 使用HEP-CE模型预测长期结局,成本以2016年美元/QALY表示,年贴现率3%。

临床怎么用

  • 在阿片类激动剂治疗项目中应优先考虑团体治疗和直接观察治疗模式。
  • 现场治疗可解决HCV治疗障碍,且具有成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many people who inject drugs in the United States have chronic hepatitis C virus (HCV). On-site treatment in opiate agonist treatment (OAT) programs addresses HCV treatment barriers, but few evidence-based models exist. METHODS: We evaluated the cost-effectiveness of HCV treatment models for OAT patients using data from a randomized trial conducted in Bronx, New York. We used a decision analytic model to compare self-administered individual treatment (SIT), group treatment (GT), directly observed therapy (DOT), and no intervention for a simulated cohort with the same demographic characteristics of trial participants. We projected long-term outcomes using an established model of HCV disease progression and treatment (hepatitis C cost-effectiveness model: HEP-CE). Incremental cost-effectiveness ratios (ICERs) are reported in 2016 US$/quality-adjusted life years (QALY), discounted 3% annually, from the healthcare sector and societal perspectives. RESULTS: For those assigned to SIT, we projected 89% would ever achieve a sustained viral response (SVR), with 7.21 QALYs and a $245 500 lifetime cost, compared to 22% achieving SVR, with 5.49 QALYs and a $161 300 lifetime cost, with no intervention. GT was more efficient than SIT, resulting in 0.33 additional QALYs and a $14 100 lower lifetime cost per person, with an ICER of $34 300/QALY, compared to no intervention. DOT was slightly more effective and costly than GT, with an ICER > $100 000/QALY, compared to GT. In probabilistic sensitivity analyses, GT and DOT were preferred in 91% of simulations at a threshold of <$100 000/QALY; conclusions were similar from the societal perspective. CONCLUSIONS: All models were associated with high rates of achieving SVR, compared to standard care. GT and DOT treatment models should be considered as cost-effective alternatives to SIT.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gutkind S, Schackman BR, Morgan JR, et al. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis. 2020. PMID: 31095683. doi:10.1093/cid/ciz384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。